Logo 1 Logo 2

Clinical Trial Details

Trial ID: L5328
Source ID: NCT00523042
Associated Drug: Insulin Aspart
Title: Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma
Acronym: iINHALE 9
Status: TERMINATED
Study Results: NO
Results:
Conditions: Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Asthma
Interventions: DRUG: insulin aspart|DRUG: inhaled human insulin
Outcome Measures: Primary: Changes in lung function, chest X-rays, or asthma exacerbation frequency, after 52 weeks of treatment | Secondary: Diabetes control measured by change in HbA1c, from baseline to end of treatment|Laboratory assessments (biochemistry, insulin antibodies, blood count), from baseline to end of treatment|Preprandial insulin doses, for the duration of the trial
Sponsor/Collaborators: Sponsor: Novo Nordisk A/S
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 10
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2007-08-30
Completion Date: 2008-02-28
Results First Posted:
Last Update Posted: 2018-09-05
Locations: Novo Nordisk Investigational Site, Fresno, California, 93720, United States|Novo Nordisk Investigational Site, New Orleans, Louisiana, 70112, United States|Novo Nordisk Investigational Site, Kansas City, Missouri, 64108, United States|Novo Nordisk Investigational Site, Columbus, Ohio, 43210, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, 19107, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, 15213, United States|Novo Nordisk Investigational Site, Houston, Texas, 77030, United States|Novo Nordisk Investigational Site, Ogden, Utah, 84403, United States|Novo Nordisk Investigational Site, Spokane, Washington, 99208, United States|Novo Nordisk Investigational Site, Broadmeadow, New South Wales, 2292, Australia|Novo Nordisk Investigational Site, Camperdown, New South Wales, 2050, Australia|Novo Nordisk Investigational Site, Keswick, South Australia, 5035, Australia|Novo Nordisk Investigational Site, Box Hill, Victoria, 3128, Australia|Novo Nordisk Investigational Site, East Ringwood, Victoria, 3135, Australia|Novo Nordisk Investigational Site, Parkville, Victoria, 3052, Australia|Novo Nordisk Investigational Site, Auchenflower, 4066, Australia|Novo Nordisk Investigational Site, Kippa Ring, 4021, Australia|Novo Nordisk Investigational Site, Belgrade, 11000, Former Serbia and Montenegro|Novo Nordisk Investigational Site, Chandigarh, Punjab, 160012, India|Novo Nordisk Investigational Site, Vellore, Tamil Nadu, 632004, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, 700020, India|Novo Nordisk Investigational Site, Hyderabad, 600034, India|Novo Nordisk Investigational Site, Mumbai, 400 067, India|Novo Nordisk Investigational Site, Pune, 411011, India|Novo Nordisk Investigational Site, Cheras, 56000, Malaysia|Novo Nordisk Investigational Site, Kota Bharu, Kelantan, 16150, Malaysia|Novo Nordisk Investigational Site, Pulau Pinang, 10990, Malaysia|Novo Nordisk Investigational Site, Kosice, 04190, Slovakia|Novo Nordisk Investigational Site, Lubochna, 03491, Slovakia|Novo Nordisk Investigational Site, Moldava nad Bodvou, 045 01, Slovakia|Novo Nordisk Investigational Site, Zilina, 01001, Slovakia|Novo Nordisk Investigational Site, Zilina, 01207, Slovakia
URL: https://clinicaltrials.gov/show/NCT00523042

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress